Additionally, while all data currently available regarding baloxavir’s clinical efficacy are limited to studies in which treatment was administered within 48 h of symptom onset, the importance of early administration of small-molecule NA inhibitors on their clinical benefit in treating influenza has long been known and informs the FDA approval of antivirals for use within 2 days of symptom onset (12). This evidence concerns the gene XK and influenza.